Article
Clinical Neurology
Aurelija Jucaite, Zsolt Cselenyi, William C. Kreisl, Eugenii A. Rabiner, Andrea Varrone, Richard E. Carson, Juha O. Rinne, Alicia Savage, Magnus Schou, Peter Johnstrom, Per Svenningsson, Olivier Rascol, Wassilios G. Meissner, Paolo Barone, Klaus Seppi, Horacio Kaufmann, Gregor K. Wenning, Werner Poewe, Lars Farde
Summary: In this study, PET imaging of TSPO showed significantly increased binding in MSA patients, with machine learning improving sensitivity. Glia imaging may support clinical MSA diagnosis and patient stratification in clinical trials on novel drug therapies.
MOVEMENT DISORDERS
(2022)
Article
Endocrinology & Metabolism
Hiroki Kato, Tatsusada Okuno, Kayako Isohashi, Toru Koda, Mikito Shimizu, Hideki Mochizuki, Yuji Nakatsuji, Jun Hatazawa
Summary: This study used quantitative PET scans to observe increased metabolism of reactive astrocytes and compromised integrity of neuronal tracts in the brains of patients with multiple sclerosis. The activation of astrocytes and the associated pathology in multiple sclerosis were visualized through quantitative 1-C-11 acetate PET imaging.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
(2021)
Article
Clinical Neurology
Christoph Mahler, Adrian-Minh Schumacher, Marcus Unterrainer, Lena Kaiser, Thomas Hollbacher, Simon Lindner, Joachim Havla, Birgit Ertl-Wagner, Maximilian Patzig, Klaus Seelos, Julia Neitzel, Matthias Maurer, Markus Krumbholz, Imke Metz, Wolfgang Bruck, Christine Stadelmann, Doron Merkler, Achim Gass, Vladimir Milenkovic, Peter Bartenstein, Nathalie L. Albert, Tania Kuempfel, Martin Kerschensteiner
Summary: The study evaluated the use of TSPO PET imaging to monitor CNS inflammation in natalizumab-associated PML lesions and distinguish them from multiple sclerosis lesions, showing potential for longitudinal monitoring of disease activity and differentiation of MS activity from PML progression.
Article
Radiology, Nuclear Medicine & Medical Imaging
Stephan P. M. Souza, Fernanda C. Frasson, Maria Emilia S. Takahashi, Gislaine B. O. Duarte, Vania P. Castro, Fernando V. Pericole, Licio A. Velloso, Carmino A. De Souza, Irene Lorand-Metze, Allan O. Santos, Celso D. Ramos
Summary: The aim of this study was to compare [F-18]FDG and [Ga-68]Ga-PSMA-11 PET/CT image findings in patients with multiple myeloma (MM). The study found that both methods can detect most lesions, but half of the lesions can only be identified by one tracer, suggesting their possible complementary role in MM.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Erik Nutma, Kelly Ceyzeriat, Sandra Amor, Stergios Tsartsalis, Philippe Millet, David R. Owen, Vassilios Papadopoulos, Benjamin B. Tournier
Summary: TSPO, located in the outer mitochondrial membrane, is considered an in vivo marker of neuroinflammation as measured with PET. Changes in TSPO expression are observed in neurodegenerative, neuroinflammatory, and neuropsychiatric diseases, but further studies are needed to fully understand its cellular underpinnings and functional significance.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Immunology
Kuriko Kagitani-Shimono, Hiroki Kato, Ryoko Kuwayama, Koji Tominaga, Shin Nabatame, Haruhiko Kishima, Jun Hatazawa, Masako Taniike
Summary: Neuroinflammation, visualized using translocator protein positron emission tomography with [C-11] DPA713, was found to be sensitive in identifying epileptic foci in child-onset focal epilepsy. The inflammation was implicated in the pathophysiology of epileptic foci caused by various etiologies, indicating a need for further research in diagnostic tools for identifying focal epileptogenic zones.
JOURNAL OF NEUROINFLAMMATION
(2021)
Review
Clinical Neurology
Laura Airas, V. Wee Yong
Summary: This review examines the activation of microglia in multiple sclerosis (MS) and its detection using positron emission tomography (PET). The study finds that persistent activation of microglia contributes to injury in MS, and PET imaging with TSPO ligands offers a means to detect and monitor microglia activation in individuals with MS. These findings highlight the importance of developing CNS penetrant inhibitors and using PET imaging as a tool for monitoring treatment responses in MS.
CURRENT OPINION IN NEUROLOGY
(2022)
Article
Clinical Neurology
Matteo Tonietto, Emilie Poirion, Andrea Lazzarotto, Vito Ricigliano, Caroline Papeix, Michel Bottlaender, Benedetta Bodini, Bruno Stankoff
Summary: This study explores the regional distribution of myelin repair in multiple sclerosis and its relationship with neurodegeneration. The findings show that periventricular white matter lesions in multiple sclerosis patients exhibit selective failure of remyelination, which is associated with choroid plexus enlargement and grey matter atrophy. The study highlights the importance of myelin repair in protecting against cortical damage in multiple sclerosis.
Article
Cell Biology
Robert K. Doot, Anthony J. Young, Ilya M. Nasrallah, Reagan R. Wetherill, Andrew Siderowf, Robert H. Mach, Jacob G. Dubroff
Summary: Neuroinflammation is an important factor in neurodegenerative diseases and is mediated by microglia. This study used [F-18]NOS PET imaging to measure neuroinflammation in idiopathic Parkinson's disease patients and found increased oxidative stress as a marker of inflammation in early-stage disease.
Article
Clinical Neurology
Antonio Canosa, Alessio Martino, Alessandro Giuliani, Cristina Moglia, Rosario Vasta, Maurizio Grassano, Francesca Palumbo, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Enrico Matteoni, Giulia Polverari, Umberto Manera, Andrea Calvo, Marco Pagani, Adriano Chio
Summary: This study aimed to evaluate the ability of brain 2-[F-18]FDG-PET to reveal the metabolic features characterizing patients with pure bulbar or spinal motor impairment. The results showed that ALS patients with bulbar onset exhibited relative hypometabolism in the bilateral precentral gyrus, and the SVM classifier performed the best.
JOURNAL OF NEUROLOGY
(2023)
Article
Multidisciplinary Sciences
Yong-Jin Park, Ji Won Lee, Hee Won Cho, Yearn Seong Choe, Kyung-Han Lee, Joon Young Choi, Ki Woong Sung, Seung Hwan Moon
Summary: The study aimed to investigate the value of C-11 methionine positron emission tomography/computed tomography (MET PET/CT) in patients with intracranial germinoma (IG). The findings showed that MET PET/CT could be a useful diagnostic tool for IGs and that tumor MET avidity may serve as a potential surrogate biomarker for HCG.
Review
Oncology
Federica Matteucci, Giovanni Paganelli, Giovanni Martinelli, Claudio Cerchione
Summary: Recent advances in the diagnosis and treatment of multiple myeloma have emphasized the importance of imaging methods, particularly PET/CT, in providing accurate information for disease localization, prognosis, and therapy response evaluation. While 18F-FDG tracer is commonly used and has high sensitivity, limitations such as physiological uptake in the bone marrow and brain have prompted research on other PET tracers for improved accuracy in multiple myeloma management.
FRONTIERS IN ONCOLOGY
(2021)
Article
Neurosciences
Chris W. J. van der Weijden, Anouk van der Hoorn, Yanming Wang, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Erik F. J. de Vries
Summary: Multiple sclerosis (MS) is an inflammatory demyelinating disease, and new treatment strategies are needed to prevent myelin damage and promote remyelination. The study showed that image-derived input functions can be used as a quantitative method for [11C]MeDAS PET, but individual arterial input functions are necessary for unbiased quantification.
Article
Clinical Neurology
S. Laaksonen, M. Saraste, M. Sucksdorff, M. Nylund, A. Vuorimaa, M. Matilainen, J. Heikkinen, L. Airas
Summary: This study aimed to explore demographic, clinical and paraclinical variables associated with later positron emission tomography (PET)-measurable innate immune cell activation. Results showed that the number of T2 lesions in diagnostic MRI, immunoglobulin G (IgG) index in diagnostic cerebrospinal fluid (CSF), and Expanded Disability Status Scale (EDSS) of ≥2.0 five years after diagnosis were associated with more prominent microglial activation. This suggests that both focal and diffuse early inflammatory phenomena impact the development of later progression-related pathology.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Biochemistry & Molecular Biology
Jeong-Hee Kim, Hang-Keun Kim, Young-Don Son, Jong-Hoon Kim
Summary: This study explored the relationship between 5-HT2A receptor availability and aggression traits in healthy individuals, and found significant positive correlations between 5-HT2A receptor availability and overall aggression score as well as scores on different aggression subscales in multiple brain regions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Julia Baguna Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Summary: This study investigated the distribution and efficacy of ofatumumab and ocrelizumab in huCD20 transgenic mice, revealing differences in tissue distribution patterns between subcutaneous and intravenous administration, with the possibility of more direct access to lymph nodes through the lymphatic system with subcutaneous administration. Additionally, preliminary findings suggest that ofatumumab may be more effective than ocrelizumab at controlling MS-like pathology in the brain.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Nicole Ruebsamen, Eline A. J. Willemse, David Leppert, Heinz Wiendl, Matthias Nauck, Andre Karch, Jens Kuhle, Klaus Berger
Summary: This study investigated whether the choice of biological matrix can affect the results when using NfL as a biomarker. The study found that although there are differences between serum and EDTA-plasma NfL, the results can be used interchangeably if standardized values are used.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Melissa Amrein, Stephanie Meier, Ibrahim Schafer, Sabine Schaedelin, Eline Willemse, Pascal Benkert, Joan Walter, Christian Puelacher, Tobias Zimmermann, Daniela Median, Caroline Egli, David Leppert, Raphael Twerenbold, Michael Zellweger, Jens Kuhle, Christian Mueller
Summary: sNfL concentration is not a reliable diagnostic biomarker for fCAD, but it can predict adverse cardiovascular outcomes, including all-cause death, cardiovascular death, and stroke/TIA.
Article
Radiology, Nuclear Medicine & Medical Imaging
Alexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, Alessandro Cagol, Reza Rahmanzadeh, Riccardo Galbusera, Po-Jui Lu, Matthias Weigel, Esther Ruberte, Ernst-Wilhelm Radue, Sabine Schaedelin, Pascal Benkert, Yaldizli Oezguer, Tim Sinnecker, Stefanie Mueller, Lutz Achtnichts, Jochen Vehoff, Giulio Disanto, Oliver Findling, Andrew Chan, Anke Salmen, Caroline Pot, Patrice Lalive, Claire Bridel, Chiara Zecca, Tobias Derfuss, Luca Remonda, Franca Wagner, Maria Vargas, Renaud Du Pasquier, Emanuele Pravata, Johannes Weber, Claudio Gobbi, David Leppert, Jens Wuerfel, Tobias Kober, Benedicte Marechal, Ricardo Corredor-Jerez, Marios Psychogios, Johanna Lieb, Ludwig Kappos, Meritxell Bach Cuadra, Jens Kuhle, Cristina Granziera
Summary: This study evaluated the accuracy of LeMan-PV software for detecting new and enlarged white matter lesions in multiple sclerosis patients. The results showed that LeMan-PV had similar sensitivity in detecting new lesions compared to other recent studies using neural networks. Although its performance is not optimal, the main advantage of LeMan-PV is that it provides automated clinical decision support integrated into the routine radiological workflow.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2023)
Article
Clinical Neurology
Stephanie Meier, Eline A. J. Willemse, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Suvitha Subramaniam, Christian Barro, Ahmed Abdelhak, Simon Thebault, Lutz Achtnichts, Patrice Lalive, Stefanie Muller, Caroline Pot, Anke Salmen, Giulio Disanto, Chiara Zecca, Marcus D'Souza, Annette Orleth, Michael Khalil, Arabella Buchmann, Renaud Du Pasquier, Ozgur Yaldizli, Tobias Derfuss, Klaus Berger, Marco Hermesdorf, Heinz Wiendl, Fredrik Piehl, Marco Battaglini, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, Claire Bridel, David Leppert, Aleksandra Maleska Maceski, Pascal Benkert, Jens Kuhle
Summary: This study found that serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) are correlated with features of disease progression in multiple sclerosis (MS) and can predict disease progression. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.
Article
Behavioral Sciences
Kamila Zondra Revendova, Chiara Starvaggi Cucuzza, Ali Manouchehrinia, Mohsen Khademi, Michal Bar, David Leppert, Elisabeth Sandberg, Russell Ouellette, Tobias Granberg, Fredrik Piehl
Summary: Neurofilament light (NfL) levels can reflect inflammatory disease activity in multiple sclerosis (MS). However, it is unclear if NfL can also be a biomarker for MS progression in treated patients without relapses and focal lesion accrual. This study found that disease modulatory therapy can reinstate an age and sex pattern for cerebrospinal fluid NfL (cNfL) similar to that of control subjects in MS patients without signs of inflammatory disease activity. There was no significant association between cNfL levels and clinical worsening, disability level, or MRI metrics.
BRAIN AND BEHAVIOR
(2023)
Article
Clinical Neurology
Arabella Buchmann, Lukas Pirpamer, Daniela Pinter, Margarete Voortman, Birgit Helmlinger, Alexander Pichler, Aleksandra Maleska Maceski, Pascal Benkert, Gerhard Bachmaier, Stefan Ropele, Markus Reindl, David Leppert, Jens Kuhle, Christian Enzinger, Michael Khalil
Summary: This study findings suggest that elevated levels of sNfL have a significant impact on brain volume changes and can indicate disease progression in pwMS over a short-term period.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Maija Saraste, Markus Matilainen, Anna Vuorimaa, Sini Laaksonen, Marcus Sucksdorff, David Leppert, Jens Kuhle, Laura Airas
Summary: This study found an association between serum neurofilament light (sNfL) and microglial activation in the brain of multiple sclerosis (MS) patients, as measured by TSPO-PET. Increased sNfL levels were correlated with a higher number and larger volume of TSPO-PET-detectable active lesions at the plaque edge and perilesional normal appearing white matter. These findings emphasize the significance of smouldering inflammation and rim-active lesions in promoting neuroaxonal damage and disease progression in MS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
David Leppert, Mitsuru Watanabe, Sabine Schaedelin, Fredrik Piehl, Roberto Furlan, Matteo Gastaldi, Jeremy Lambert, Bjorn Evertsson, Katharina Fink, Takuya Matsushita, Katsuhisa Masaki, Noriko Isobe, Jun-ichi Kira, Pascal Benkert, Aleksandra Maceski, Eline Willemse, Johanna Oechtering, Annette Orleth, Stephanie Meier, Jens Kuhle
Summary: This study aimed to determine the differences in granulocyte activation markers (GAM) between neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS), and whether they are associated with neurological impairment. The results showed that GAM and adhesion molecules were higher in acute NMOSD compared to RRMS and correlated with clinical disability scores. The composite of GAM can be used as a reliable biomarker to differentiate NMOSD from MS, including aAQP4(-) NMOSD.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Amin Ziaei, Zahra Nasr, Janace Hart, Carla Francisco, Alice Rutatangwa, David Leppert, Jens Kuhle, Eoin Flanagan, Emmanuelle Waubant
Summary: The study investigated the association between serum neurofilament light chain (sNfL) levels and time from disease activity in pediatric-onset multiple sclerosis (POMS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The results showed that high sNfL levels were closely associated with clinical or MRI events in POMS and MOGAD patients.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Marisol Herrera-Rivero, Edith Hofer, Aleksandra Maceski, David Leppert, Pascal Benkert, Jens Kuhle, Reinhold Schmidt, Michael Khalil, Heinz Wiendl, Monika Stoll, Klaus Berger
Summary: This study investigated the genetic factors underlying serum NfL levels in individuals without neurological conditions. The discovery GWAS identified 12 genomic loci associated with sNfL levels, suggesting that polygenic regulation of neuronal processes, inflammation, metabolism, and clearance contribute to the variability of NfL in the circulation.
FRONTIERS IN NEUROLOGY
(2023)
Meeting Abstract
Clinical Neurology
R. Demjaha, E. Hofer, L. Pirpamer, A. Buchmann, D. Pinter, D. Leppert, P. Benkert, J. Kuhle, S. Ropele, R. Schmidt, J. H. Cole, C. Enzinger, M. Khalil
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
J. Oechtering, K. Stein, S. Schadelin, M. Limberg, A. Orleth, A. Maceski, S. Meier, E. Willemse, F. Qureshi, F. Rubio Da Costa, W. Hu, I. Heijnen, A. Regeniter, T. Derfuss, P. Benkert, H. Wiendl, C. Granziera, L. Kappos, M. Trendelenburg, D. Leppert, J. D. Luenemann, J. Kuhle
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
J. Kuhle, J. Oechtering, E. A. Willemse, D. Leppert, C. Granziera, P. Benkert, A. Maleska, S. Schaedelin, F. Zhang, F. Rubio da Costa, V. Gehman, F. Qureshi
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Cedric Hirzel, Denis Grandgirard, Bernard Surial, Manon F. Wider, David Leppert, Jens Kuhle, Laura N. Walti, Joerg C. Schefold, Thibaud Spinetti, Franziska Suter-Riniker, Ronald Dijkman, Stephen L. Leib
Summary: Severe COVID-19 is associated with increased levels of cytokines and subsequent neuronal injury as reflected by elevated levels of sNfL. Patients with severe disease develop higher levels of neutralizing antibodies and SARS-CoV-2-specific T cells. However, mounting a strong virus-specific humoral and cell-mediated immune response does not protect against neuro-axonal damage.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2022)